PMP
MCID: PSD007
MIFTS: 52

Pseudomyxoma Peritonei (PMP)

Categories: Cancer diseases, Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Pseudomyxoma Peritonei

MalaCards integrated aliases for Pseudomyxoma Peritonei:

Name: Pseudomyxoma Peritonei 12 73 20 58 54 44 15 17 70
Gelatinous Ascites 20 58
Adenomucinosis 20 58
Pmp 20 58
Syndrome of Pseudomyxoma Peritonei 20
Mucinous Ascites 12

Characteristics:

Orphanet epidemiological data:

58
pseudomyxoma peritonei
Prevalence: 1-9/1000000 (Worldwide); Age of onset: Adult; Age of death: any age;

Classifications:



External Ids:

Disease Ontology 12 DOID:3559
MeSH 44 D011553
NCIt 50 C3345
SNOMED-CT 67 307601000
MESH via Orphanet 45 D011553
ICD10 via Orphanet 33 C78.6
UMLS via Orphanet 71 C0033822
Orphanet 58 ORPHA26790
UMLS 70 C0033822

Summaries for Pseudomyxoma Peritonei

GARD : 20 Pseudomyxoma peritonei (PMP) is a rare disease characterized by the presence of mucin in the abdominal ( peritoneal ) cavity. While the most common cause of PMP is appendix cancer, several types of tumors (including non-cancerous tumors ) can cause PMP. Signs and symptoms may include an increase in abdominal size or bloating; inguinal hernia (in men); an ovarian mass that may be felt during a routine pelvic exam (in women); pain or discomfort in the abdomen; and/or appendicitis. Treatment depends on the underlying cause of the condition (the location and type of the original tumor, including whether it is malignant ) and the extent of spreading. A combination of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is often the most successful treatment.

MalaCards based summary : Pseudomyxoma Peritonei, also known as gelatinous ascites, is related to appendix adenocarcinoma and intestinal obstruction. An important gene associated with Pseudomyxoma Peritonei is KRT7 (Keratin 7), and among its related pathways/superpathways are Metabolism of proteins and HIV Life Cycle. The drugs Thalidomide and Ipilimumab have been mentioned in the context of this disorder. Affiliated tissues include appendix, ovary and colon, and related phenotypes are ascites and abnormality of the peritoneum

Disease Ontology : 12 An appendix cancer that is characterized by progressive accumulation of mucus-secreting tumor cells within the abdomen and pelvis.

Wikipedia : 73 Pseudomyxoma peritonei (PMP) is a clinical condition caused by cancerous cells (mucinous adenocarcinoma)... more...

Related Diseases for Pseudomyxoma Peritonei

Diseases related to Pseudomyxoma Peritonei via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 539)
# Related Disease Score Top Affiliating Genes
1 appendix adenocarcinoma 31.2 KRT7 KRT20 KRAS GNAS CDX2
2 intestinal obstruction 30.8 KRT7 KRT20 CEACAM5 CDX2
3 benign mesothelioma 30.8 KRT7 KRT20 CEACAM5
4 peritoneal mesothelioma 30.6 MUC16 MUC1 CEACAM5
5 colloid carcinoma of the pancreas 30.5 MUC5AC MUC1
6 mucinous cystadenocarcinoma 30.4 MUC2 MUC16 MUC1 KRT7 KRT20 CEACAM5
7 jejunal neoplasm 30.4 MUC6 KRT7 KRT20
8 urachal adenocarcinoma 30.4 KRAS GNAS CEACAM5
9 rectum cancer 30.3 KRT20 KRAS CEACAM5
10 mucinous adenocarcinoma 30.3 TP53 MUC5AC MUC16 MUC1 KRT7 KRT20
11 appendiceal neoplasm 30.3 KRT7 KRAS GNAS CEACAM5 CDX2
12 tuberculous peritonitis 30.2 MUC16 CEACAM5
13 adenomyoma 30.1 MUC1 KRT7 CTNNB1
14 goblet cell carcinoid 30.1 KRT20 CTNNB1 CDH1
15 krukenberg carcinoma 30.0 KRT7 KRT20 CEACAM5 CDX2
16 transverse colon cancer 29.9 KRT7 KRT20 KRAS CEACAM5
17 cystadenocarcinoma 29.9 TP53 MUC5AC MUC2 MUC16 MUC1 KRT7
18 ovarian mucinous adenocarcinoma 29.8 MUC5AC MUC2 KRT7 KRT20 CEACAM5 CDX2
19 adenocarcinoma in situ 29.7 KRT7 KRT20 KRAS CEACAM5 CDX2
20 cystic teratoma 29.7 TP53 MUC6 MUC5AC KRT7 KRT20 KRAS
21 peritoneum cancer 29.7 TP53 KRT7 CEACAM5
22 ovarian mucinous neoplasm 29.6 MUC6 MUC5AC KRT7 KRT20 KRAS CEACAM5
23 cystadenoma 29.6 REG4 MUC6 MUC5AC MUC16 MUC1 KRT7
24 mature teratoma 29.5 TP53 KRT7 KRAS CEACAM5
25 endometrial hyperplasia 29.4 TP53 KRAS CTNNB1
26 colorectal adenoma 29.4 TP53 KRAS CTNNB1 CDH1
27 myoma 29.3 TP53 MUC16 KRAS CEACAM5
28 teratoma 29.2 TP53 KRT7 KRT20 KRAS CTNNB1 CEACAM5
29 endometrial adenocarcinoma 28.9 TP53 MUC1 KRT7 KRAS CTNNB1 CDH1
30 microinvasive gastric cancer 28.9 TP53 MUC6 MUC5AC CEACAM5 CDX2 CDH1
31 mesothelioma, malignant 28.8 MUC16 MUC1 KRT7 KRT20 CTNNB1 CEACAM5
32 endocervical adenocarcinoma 28.5 TP53 MUC6 MUC5AC MUC1 KRT7 KRT20
33 appendix cancer 28.5 TP53 REG4 MUC6 MUC5AC MUC1 KRT7
34 tubular adenocarcinoma 28.5 MUC5AC MUC2 MUC1 KRT7 KRT20 CTNNB1
35 adenoma 28.5 TP53 MUC6 MUC5AC MUC1 KRT7 KRT20
36 ovarian cancer 28.3 TP53 MUC5AC MUC16 MUC1 KRT7 KRT20
37 intrahepatic cholangiocarcinoma 28.2 TP53 MUC5AC MUC1 KRT7 KRT20 KRAS
38 ovarian cystadenocarcinoma 28.2 TP53 MUC6 MUC5AC MUC16 MUC1 KRAS
39 villous adenoma 28.2 TP53 MUC6 MUC5AC MUC1 KRT7 KRT20
40 adenocarcinoma 28.2 TP53 MUC1 KRT7 KRT20 KRAS GNAS
41 gastric adenocarcinoma 28.0 TP53 KRT20 KRAS GNAS CTNNB1 CEACAM5
42 colorectal adenocarcinoma 28.0 TP53 MUC1 KRT7 KRT20 KRAS CTNNB1
43 endometrial cancer 27.8 TP53 MUC16 MUC1 KRT7 KRT20 KRAS
44 cholangiocarcinoma 27.6 TP53 MUC5AC MUC2 MUC1 KRT7 KRT20
45 signet ring cell adenocarcinoma 27.2 TP53 REG4 MUC6 MUC5AC MUC2 MUC1
46 lung cancer susceptibility 3 27.0 TP53 MUC5AC MUC16 MUC1 KRT7 KRT20
47 pancreatic cancer 26.9 TP53 MUC6 MUC5AC MUC2 MUC16 MUC1
48 handl syndrome 11.0
49 appendicitis 10.7
50 inguinal hernia 10.6

Graphical network of the top 20 diseases related to Pseudomyxoma Peritonei:



Diseases related to Pseudomyxoma Peritonei

Symptoms & Phenotypes for Pseudomyxoma Peritonei

Human phenotypes related to Pseudomyxoma Peritonei:

58 31 (show all 12)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 ascites 58 31 hallmark (90%) Very frequent (99-80%) HP:0001541
2 abnormality of the peritoneum 58 31 hallmark (90%) Very frequent (99-80%) HP:0002585
3 abnormality of the abdominal wall 58 31 hallmark (90%) Very frequent (99-80%) HP:0004298
4 inflammation of the large intestine 58 31 frequent (33%) Frequent (79-30%) HP:0002037
5 nausea and vomiting 58 31 occasional (7.5%) Occasional (29-5%) HP:0002017
6 constipation 58 31 occasional (7.5%) Occasional (29-5%) HP:0002019
7 respiratory insufficiency 58 31 occasional (7.5%) Occasional (29-5%) HP:0002093
8 hernia 58 31 occasional (7.5%) Occasional (29-5%) HP:0100790
9 abdominal pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0002027
10 weight loss 58 31 occasional (7.5%) Occasional (29-5%) HP:0001824
11 intestinal obstruction 58 31 occasional (7.5%) Occasional (29-5%) HP:0005214
12 lymphadenopathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0002716

MGI Mouse Phenotypes related to Pseudomyxoma Peritonei:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.5 CDH1 CDX2 CTNNB1 KRAS MUC2 MUC5AC
2 neoplasm MP:0002006 9.17 CDH1 CDX2 CTNNB1 GNAS KRAS MUC2

Drugs & Therapeutics for Pseudomyxoma Peritonei

Drugs for Pseudomyxoma Peritonei (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 67)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
2
Ipilimumab Approved Phase 2 477202-00-9
3
nivolumab Approved Phase 2 946414-94-4
4
Amoxicillin Approved, Vet_approved Phase 2 26787-78-0 33613
5
Dexlansoprazole Approved, Investigational Phase 2 138530-94-6, 103577-45-3 9578005
6
Clarithromycin Approved Phase 2 81103-11-9 84029
7
Lansoprazole Approved, Investigational Phase 2 103577-45-3 3883
8
carbamide peroxide Approved Phase 2 124-43-6
9
Acetylcysteine Approved, Investigational Phase 1, Phase 2 616-91-1 12035
10
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 43805 6857599
11
leucovorin Approved Phase 2 58-05-9 6006
12
Fluorouracil Approved Phase 2 51-21-8 3385
13
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
14 Cola Phase 2
15 Angiogenesis Inhibitors Phase 2
16 Mitomycins Phase 2
17 Alkylating Agents Phase 2
18 Antineoplastic Agents, Immunological Phase 2
19 Antibodies Phase 2
20 Immunoglobulins Phase 2
21 Antibodies, Monoclonal Phase 2
22 Antibiotics, Antitubercular Phase 2
23 Anti-Bacterial Agents Phase 2
24 Gastrointestinal Agents Phase 2
25 Cytochrome P-450 CYP3A Inhibitors Phase 2
26 Cytochrome P-450 Enzyme Inhibitors Phase 2
27 Anti-Ulcer Agents Phase 2
28 Proton Pump Inhibitors Phase 2
29 Antacids Phase 2
30 Respiratory System Agents Phase 1, Phase 2
31 Expectorants Phase 1, Phase 2
32 Antioxidants Phase 1, Phase 2
33 N-monoacetylcystine Phase 1, Phase 2
34 Antiviral Agents Phase 1, Phase 2
35 Anti-Infective Agents Phase 1, Phase 2
36 Vitamin B9 Phase 2
37 Nutrients Phase 2
38 Micronutrients Phase 2
39 Trace Elements Phase 2
40 Vitamin B Complex Phase 2
41 Vitamins Phase 2
42 Antidotes Phase 2
43 Folate Phase 2
44 Antimetabolites Phase 2
45 Protective Agents Phase 2
46 Immunosuppressive Agents Phase 2
47 Immunologic Factors Phase 2
48
Floxuridine Approved Phase 1 50-91-9 5790
49
Levoleucovorin Approved, Investigational Phase 1 68538-85-2 149436
50
Gemcitabine Approved Phase 1 95058-81-4 60750

Interventional clinical trials:

(show all 26)
# Name Status NCT ID Phase Drugs
1 Effects of High Intra-abdominal Pressure on Tissue Diffusion and Pharmacokinetics of Cisplatin During HIPEC Completed NCT02949791 Phase 2
2 Single Arm Study Treating Patients of Peritoneal Surface Malignancy (Colorectal, Appendical, Pseudomyxoma, Gastric) With Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin-C Completed NCT02040142 Phase 2 Mitomycin C
3 Phase II Trial of Adjuvant Thalidomide Following Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Carcinomatosis or Adenomucinosis From Colorectal/Appendiceal Cancer Completed NCT00310076 Phase 2 thalidomide
4 A Randomized Phase 2 Trial of Flat Dose vs. Weight-based Dose of Intra-peritoneal (IP) Chemotherapy for Patients Undergoing Cytoreductive Surgery and Heated Intra-peritoneal Chemotherapy (CRS/HIPEC) for Advanced Gastrointestinal Malignancy Recruiting NCT04779554 Phase 2 Mitomycin C, flat dose 40 mg;Mitomycin C, weight-based dose 12.5 mg/m2
5 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
6 Clinical Trial to Define the Effect of Perioperative H. Pylori Eradication With Antibiotic Treatment on Long Term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin Undergoing Cytoreductive Surgery/Hyperthermic Intraperitoneal Chemotherapy Active, not recruiting NCT02387203 Phase 2 PrevPac (Prevacid, Amoxicillin, Clarithromycin)
7 Injection of Bromelain and Acetylcysteine in Combination Into Recurrent Mucinous Tumour or Pseudomyxoma Peritonei Not yet recruiting NCT03976973 Phase 1, Phase 2 Bromelain, Stem;Acetylcysteine
8 A Phase II Study of Surgical Debulking With Peritonectomy and Biweekly Intraperitoneal 5FU With Systemic Oxaliplatin/5FU/Leucovorin in Patients With Pseudomyxoma Peritonei or Peritoneal Carcinomatosis Terminated NCT00352755 Phase 2 Intraperitoneal 5FU;FOLFOX
9 A Phase I Study of Intraperitoneal Oxaliplatin Alone and in Combination With Intraperitoneal Floxuridine and Leucovorin in Patients With Advanced Metastatic Cancer Confined to the Peritoneal Cavity Completed NCT00005860 Phase 1 floxuridine;leucovorin calcium;oxaliplatin
10 A Phase 1 Study of Carboplatin and Gemcitabine Chemotherapy and Stereotactic Body Radiosurgery for the Palliative Treatment of Persistent or Recurrent Gynecologic Cancer Completed NCT01652794 Phase 1 carboplatin;gemcitabine hydrochloride
11 A Phase 1 Study of SGN-STNV in Advanced Solid Tumors Recruiting NCT04665921 Phase 1 SGN-STNV
12 Phase I Trial of Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy With Nanoliposomal Irinotecan in Patients With Peritoneal Surface Malignancies Recruiting NCT04088786 Phase 1 nanoliposomal irinotecan
13 French National Registry of Rare Peritoneal Surface Malignancies (RENAPE Registry) Unknown status NCT02834169
14 Comparison Between Cyotreductive Surgery and Debulking Surgery in Patients With Pseudomyxoma Peritonei Unknown status NCT01427101
15 A Survey of the Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients Completed NCT02374411
16 HOPE Program: Quality of Life Enhancement and Survivorship Care Completed NCT01126346
17 A Biobehavioral Intervention for Patients With Gynecologic or Breast Cancer Recurrence Completed NCT01764789
18 Thrombin Generation and Platelet Activation in Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Completed NCT03034850
19 A Randomized Crossover Trial of Systemic Chemotherapy in Patients With Metastatic Well-Differentiated Mucinous Appendiceal Adenocarcinomas With Pseudomyxoma Peritonei Recruiting NCT01946854
20 A Cohort Study of the Gastrointestinal Microbiome in Appendiceal Cancer With Peritoneal Spread Recruiting NCT02599116
21 Prospective Observational Study of Peritoneal Surface Malignancies (PSM) - Characterization, Models and Treatment Strategies. Recruiting NCT02073500
22 Register With Data From Patients With the Diagnosis of a Peritoneal Surface Malignancy, for Which Cytoreductive Surgery and Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) is Performed Recruiting NCT01617382
23 Multicenter, International Online Documentation of Indications and Results of Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC Und PITAC) for Treating Malignant Peritoneal and Pleural Diseases Recruiting NCT03210298
24 Recovery of Quality of Life After Cytoreductive Surgery and Intraperitoneal Chemotherapy for Colorectal Cancer and Pseudomyxoma Peritonei Not yet recruiting NCT03503071
25 Implementation of a Cardiac Coherence Program to Reduce Anxiety in Patients With Peritoneal Carcinosis Treated by Surgery: Randomized Pilot Study Not yet recruiting NCT04024917
26 An Interpretative Phenomenological Analysis of 'Recovery' Following Complete Cytoreductive Surgery. Withdrawn NCT04125225

Search NIH Clinical Center for Pseudomyxoma Peritonei

Cochrane evidence based reviews: pseudomyxoma peritonei

Genetic Tests for Pseudomyxoma Peritonei

Anatomical Context for Pseudomyxoma Peritonei

MalaCards organs/tissues related to Pseudomyxoma Peritonei:

40
Appendix, Ovary, Colon, Small Intestine, Spleen, Liver, Pancreas

Publications for Pseudomyxoma Peritonei

Articles related to Pseudomyxoma Peritonei:

(show top 50) (show all 1459)
# Title Authors PMID Year
1
CDX-2 expression in pseudomyxoma peritonei: a clinicopathological study of 42 cases. 54 61
16978201 2006
2
MUC2 is a molecular marker for pseudomyxoma peritonei. 61 54
12218214 2002
3
Pseudomyxoma peritonei is a disease of MUC2-expressing goblet cells. 61 54
12163380 2002
4
Mucinous tumors of the vermiform appendix and ovary, and pseudomyxoma peritonei: histogenetic implications of cytokeratin 7 expression. 54 61
9308728 1997
5
Immunohistochemical study of cytokeratin 7 for the differential diagnosis of adenocarcinomas in the ovary. 61 54
7506222 1993
6
High-grade appendiceal mucinous neoplasm presenting as a giant appendiceal mucocele. 61
33680275 2021
7
Correction to: Intraperitoneal mitomycin C improves survival compared to cytoreductive surgery alone in an experimental model of highgrade pseudomyxoma peritonei. 61
33649933 2021
8
The mutational landscape and prognostic indicators of pseudomyxoma peritonei originating from the ovary. 61
33403690 2021
9
Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery. 61
33502464 2021
10
Reply to comments on "Efficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei". 61
33547970 2021
11
Huge and Unique Pseudomyxoma Peritonei. 61
33679016 2021
12
The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery. 61
33502455 2021
13
Is it a case series? Comment on "Efficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei". 61
33385276 2021
14
A case of pseudomyxoma peritonei successfully treated with trifluridine/tipiracil (TAS-102) and bevacizumab after palliative debulking surgery. 61
33752412 2021
15
Molecular and clinicopathological features of appendiceal mucinous neoplasms. 61
32821969 2021
16
ASO Visual Abstract: From the Ronnett to the PSOGI Classification System for Pseudomyxoma Peritonei: A Validation Study. 61
33650062 2021
17
Parenteral nutrition complications in palliative medicine. 61
33771817 2021
18
Emergency laparoscopic ileocecal resection for a low-grade appendiceal mucinous neoplasm with impending rupture: A case report. 61
33609942 2021
19
Mid-Term Audit of a National Peritoneal Surface Malignancy Program Implementation in a Low Middle Income Country: The Moroccan Experience. 61
33802609 2021
20
Primary mucinous ovarian tumors vs. ovarian metastases from gastrointestinal tract, pancreas and biliary tree: a review of current problematics. 61
33706757 2021
21
Two-step cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei with high peritoneal carcinomatosis index. 61
33622339 2021
22
Acute Chylopericardium With Tamponade and Cardiac Arrest With Pseudomyxoma Peritonei. 61
33548186 2021
23
Evaluation of the significance of pseudomyxoma peritonei patients based on the Peritoneal Surface Oncology Group International (PSOGI) classification. 61
33622598 2021
24
Consensuses and controversies on pseudomyxoma peritonei: a review of the published consensus statements and guidelines. 61
33581733 2021
25
Western Australian Peritonectomy Service: a review of the first 6 years of operation of a low-volume peritonectomy centre. 61
33590661 2021
26
A case of Endometrioid endometrial adenocarcinoma with synchronous low-grade Appendiceal mucinous neoplasm and Pseudomyxoma peritonei. 61
33605928 2021
27
The Frontiers of Appendiceal Controversies: Mucinous Neoplasms and Pseudomyxoma Peritonei. 61
33417324 2021
28
Jelly-like Pleural Effusions: An Uncommon Manifestation of Pseudomyxoma Peritonei. 61
33618915 2021
29
ASO Author Reflection: The End of the Tower of Babel in Pseudomyxoma Peritonei. 61
33481126 2021
30
Appendiceal tumours and pseudomyxoma peritonei: Literature review with PSOGI/EURACAN clinical practice guidelines for diagnosis and treatment. 61
32199769 2021
31
From the Ronnett to the PSOGI Classification System for Pseudomyxoma Peritonei: A Validation Study. 61
33471266 2021
32
Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for a limited low-grade pseudomyxoma peritonei-a video vignette. 61
33070418 2021
33
Estimating the Prevalence of Pseudomyxoma Peritonei in Europe Using a Novel Statistical Method. 61
32488520 2021
34
Pseudomyxoma pleurii: unusual location of a rare disease. 61
33294092 2021
35
Long-term outcomes for patients with peritoneal acellular mucinosis secondary to low grade appendiceal mucinous neoplasms. 61
33092969 2021
36
Severe Erosive Esophagitis Secondary to Gastric Outlet Obstruction Related to Pseudomyxoma Peritonei. 61
33447626 2021
37
The Delphi and GRADE methodology used in the PSOGI 2018 consensus statement on Pseudomyxoma Peritonei and Peritoneal Mesothelioma. 61
30954350 2021
38
Phase II randomized study on tissue distribution and pharmacokinetics of cisplatin according to different levels of intra-abdominal pressure (IAP) during HIPEC (NCT02949791). 61
31262599 2021
39
A Multi-institutional Study of Peritoneal Recurrence Following Resection of Low-grade Appendiceal Mucinous Neoplasms. 61
33415564 2021
40
From Diagnosis to Management; Mucocele of Stump Appendicitis, Extremely Rare Finding in an Uncommon Surgical Disease: Literature Review. 61
33628502 2021
41
Hyperthermic intrathoracic chemotherapy combined to iterative cytoreductive surgery to treat a pleural carcinosis from psudomixoma peritonei. A case report. 61
33506925 2021
42
Germline and somatic genetic alterations in two first-degree relatives with appendiceal low-grade mucinous carcinoma peritonei. 61
33363901 2020
43
Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for perforated low-grade appendiceal mucinous neoplasms. 61
31993814 2020
44
ASO Author Reflections: Estimating the Prevalence of Pseudomyxoma Peritonei in Europe Using a Novel Statistical Method. 61
32495284 2020
45
A general overview of mucocele of appendix. 61
33681010 2020
46
Totally implantable venous access port infection caused by Staphylococcus pseudintermedius: Possible transmission from a companion dog to a human. 61
32768341 2020
47
Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for limited peritoneal metastasis. The PSOGI international collaborative registry. 61
33298341 2020
48
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei of appendiceal origin: result of a single centre study. 61
32410159 2020
49
Incidental Diagnosis of Pseudomyxoma Peritonei After Emergent Splenectomy. 61
33342260 2020
50
Cytoreductive Surgery and Hyperthermic Chemotherapy for Intrathoracic Pseudomyxoma Peritonei. 61
32553770 2020

Variations for Pseudomyxoma Peritonei

Expression for Pseudomyxoma Peritonei

Search GEO for disease gene expression data for Pseudomyxoma Peritonei.

Pathways for Pseudomyxoma Peritonei

Pathways related to Pseudomyxoma Peritonei according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.57 TP53 MUC6 MUC5AC MUC2 MUC16 MUC1
2
Show member pathways
13.51 MUC6 MUC5AC MUC2 MUC16 MUC1 KRAS
3
Show member pathways
12.8 TP53 KRAS GNAS CTNNB1 CDH1
4 12.63 TP53 KRAS GNAS CTNNB1 CDH1
5 12.36 MUC1 KRT7 KRT20 CDH1
6
Show member pathways
12.3 TP53 MUC1 KRAS CTNNB1 CDH1
7 12.25 TP53 GNAS CTNNB1 CDH1
8
Show member pathways
12.15 MUC1 KRAS CTNNB1 CDH1
9
Show member pathways
12.06 MUC6 MUC5AC MUC2 MUC16 MUC1
10
Show member pathways
12.04 MUC6 MUC5AC MUC2 MUC16 MUC1 KRAS
11 11.98 TP53 KRAS GNAS CTNNB1 CDH1
12 11.95 TP53 KRAS CTNNB1 CDH1
13
Show member pathways
11.88 MUC6 MUC5AC MUC2 MUC16 MUC1
14 11.87 KRAS CTNNB1 CDH1
15 11.86 TP53 KRAS CTNNB1
16 11.83 TP53 KRAS CTNNB1
17
Show member pathways
11.83 TP53 REG4 MUC2 KRAS CTNNB1 CDX2
18 11.81 TP53 KRAS CTNNB1
19 11.74 REG4 MUC1 CTNNB1 CEACAM5 CDH1
20 11.56 TP53 KRAS CDH1
21
Show member pathways
11.39 MUC6 MUC5AC MUC2 MUC16 MUC1
22 10.69 CTNNB1 CDH1

GO Terms for Pseudomyxoma Peritonei

Cellular components related to Pseudomyxoma Peritonei according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.92 REG4 MUC6 MUC5AC MUC16 MUC1 GNAS
2 extracellular exosome GO:0070062 9.76 MUC5AC MUC16 MUC1 KRT7 GNAS CTNNB1
3 flotillin complex GO:0016600 9.26 CTNNB1 CDH1
4 Golgi lumen GO:0005796 9.02 MUC6 MUC5AC MUC2 MUC16 MUC1
5 mucus layer GO:0070701 8.96 MUC5AC MUC2

Biological processes related to Pseudomyxoma Peritonei according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.71 TP53 GNAS CTNNB1 CDH1
2 epithelial tube branching involved in lung morphogenesis GO:0060441 9.48 KRAS CTNNB1
3 maintenance of gastrointestinal epithelium GO:0030277 9.46 MUC6 MUC2
4 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.43 TP53 MUC1
5 entry of bacterium into host cell GO:0035635 9.37 CTNNB1 CDH1
6 O-glycan processing GO:0016266 9.35 MUC6 MUC5AC MUC2 MUC16 MUC1
7 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.32 TP53 MUC1
8 cellular response to indole-3-methanol GO:0071681 9.26 CTNNB1 CDH1
9 hair follicle placode formation GO:0060789 9.16 GNAS CTNNB1
10 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.1 MUC6 MUC5AC MUC2 MUC16 MUC1 KRAS

Sources for Pseudomyxoma Peritonei

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....